AI Article Synopsis

  • The study evaluated a new defibrillation lead design with a small electrode surface to determine its safety and effectiveness compared to a conventional lead.
  • 542 patients received either the new model or a standard model, with no significant differences in lead success rates or defibrillation effectiveness between the two groups.
  • Findings showed that while the new lead increased pacing impedance and had slightly smaller R-wave amplitudes, it did not lead to more adverse events or affect patient survival negatively.

Article Abstract

Background: Pacing leads with a small electrode surface for high-impedance stimulation have been shown to prolong pacemaker longevity, but no sufficient data is available on the safety and feasibility of a defibrillation lead with this novel design.

Methods: We evaluated the clinical performance of a tined, steroid-eluting defibrillation lead with a small electrode surface area (model 6944) in a prospective multicenter study. A total of 542 patients with conventional indications for an implantable cardioverter defibrillator were randomized 1:1 to receive either the model 6944 or a tined, steroid-eluting defibrillation lead with a conventional sized electrode surface area (model 6942). Device performance and electrical parameters were evaluated at implant and 1, 3, 6, and 12 months thereafter (mean follow-up 11.3 +/- 5.6 months).

Results: Baseline characteristics, lead implant success rates, and defibrillation thresholds did not differ significantly between the 2 groups. While pacing thresholds did not differ significantly during follow-up, pacing impedance was approximately twice as high in the model 6944 as in the model 6942 lead (P <.0001). Mean R-wave amplitudes were smaller in patients with a 6944 (9.1 +/- 3.1 mV vs 9.8 +/- 3.6 mV for model 6942, P <.05), but remained stable within both groups throughout the observation period. The total number of ventricular lead-related adverse events and patient survival did not differ significantly between the 2 groups.

Conclusions: The use of a defibrillation lead with a small electrode surface for high-efficiency pacing is safe and feasible and increases pacing impedance without significantly compromising clinical performance.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0002-8703(03)00411-3DOI Listing

Publication Analysis

Top Keywords

defibrillation lead
16
electrode surface
16
model 6944
12
lead small
8
surface high-impedance
8
small electrode
8
tined steroid-eluting
8
steroid-eluting defibrillation
8
surface area
8
area model
8

Similar Publications

Prognostic role of aetiological agent vs. clinical pattern in candidates to lead extraction for cardiac implantable electronic device infections.

Sci Rep

December 2024

Department of Medical and Surgical Sciences, Institute of Cardiology, University of Bologna, Policlinico S.Orsola-Malpighi, via Massarenti 9, Bologna, 40138, Italy.

Cardiac implantable electronic devices infections (CIEDI) are associated with poor survival despite the improvement in transvenous lead extraction (TLE). Aetiology and systemic involvement are driving factors of clinical outcomes. The aim of this study was to explore their contribute on overall mortality.

View Article and Find Full Text PDF

Background: Ventricular arrhythmia is a common type of arrhythmia observed in clinical practice. It is primarily characterized by premature ventricular contractions, ventricular tachycardia, and ventricular fibrillation. Abnormal formation or transmission of cardiac electrical impulses in patients affects cardiac ejection function.

View Article and Find Full Text PDF

Background: An atrioventricular defibrillator system with a floating atrial dipole (VDD ICD) can provide atrial sensing by a single lead. Our aim was to compare the arrhythmia detection efficacy of VDD ICDs with conventional single- (VVI) and dual-chamber (DDD) defibrillators.

Methods: Data from consecutive patients undergoing ICD implantation were retrospectively analyzed.

View Article and Find Full Text PDF
Article Synopsis
  • Cardiac resynchronization therapy (CRT) is effective for treating heart failure but is under-researched in patients with common comorbidities like atrial fibrillation (AF).
  • The SMART registry enrolled 2035 patients to assess CRT response based on clinical outcomes over 12 months, focusing on factors like all-cause mortality, hospitalizations, and quality of life.
  • Results showed 58.9% of patients improved, but factors like age, AF, and diabetes were linked to lower CRT responsiveness, with patients having AF experiencing higher rates of hospitalizations and mortality compared to those in normal rhythm.
View Article and Find Full Text PDF

The benefits of permanent cardiac pacing have been widely demonstrated. However, the literature on complications remains inconsistent. We lack precise information about the frequency of complications and their predictive factors in our center.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!